Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 13/20 | 0.82 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.82 |
| ▸ | CDK9 | P50750 | 4/20 | 0.82 |
| ▸ | CAMK2D | Q13557 | 3/20 | 0.82 |
| ▸ | JAK2 | O60674 | 2/20 | 0.82 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.82 |
| ▸ | PLK4 | O00444 | 1/20 | 0.82 |
| ▸ | STK10 | O94804 | 1/20 | 0.82 |
| ▸ | ABL1 | P00519 | 1/20 | 0.82 |
| ▸ | PRKCB | P05771 | 1/20 | 0.82 |
| ▸ | MET | P08581 | 1/20 | 0.82 |
| ▸ | TOP2A | P11388 | 1/20 | 0.82 |
| ▸ | PRKCA | P17252 | 1/20 | 0.82 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.82 |
| ▸ | JAK1 | P23458 | 1/20 | 0.82 |
| ▸ | MARK3 | P27448 | 1/20 | 0.82 |
| ▸ | TYK2 | P29597 | 1/20 | 0.82 |
| ▸ | ABL2 | P42684 | 1/20 | 0.82 |
| ▸ | CDK17 | Q00537 | 1/20 | 0.82 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14883444 | 0.91 | JAK3 (0.78) | JAK3ROCK2CDK9CAMK2DJAK2 | |
| Decernotinib SCHEMBL29349797 | 0.91 | JAK3 (1.00) | JAK3ROCK2CDK9CAMK2DJAK2 | |
| Decernotinib SCHEMBL29393666 | 0.91 | JAK3 (1.00) | JAK3ROCK2CDK9CAMK2DJAK2 | |
| SCHEMBL26192204 | 0.91 | JAK3 (0.90) | JAK3ROCK2CDK9CAMK2DJAK2 | |
| Decernotinib SCHEMBL14487963 | 0.91 | JAK3 (1.00) | JAK3ROCK2CDK9CAMK2DJAK2 | |
| Decernotinib SCHEMBL24212406 | 0.91 | JAK3 (1.00) | JAK3ROCK2CDK9CAMK2DJAK2 | |
| Decernotinib SCHEMBL2630387 | 0.91 | JAK3 (1.00) | JAK3ROCK2CDK9CAMK2DJAK2 | |
| SCHEMBL2630435 | 0.91 | JAK3 (0.80) | JAK3ROCK2CDK9CAMK2DJAK2 | |
| SCHEMBL2630419 | 0.90 | JAK3 (0.67) | JAK3ROCK2CDK9CAMK2DJAK2 | |
| SCHEMBL2630437 | 0.90 | JAK3 (0.79) | JAK3ROCK2CDK9CAMK2DJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9120790-B2 | Azaindoles useful as inhibitors of Janus kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-09-01 | — | — | US | disclosed |
| US-9120790-B2 | Azaindoles useful as inhibitors of Janus kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-09-01 | — | — | US | disclosed |
| US-20140357557-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2014-12-04 | — | — | US | disclosed |
| US-8822681-B2 | Azaindoles useful as inhibitors of janus kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822681-B2 | Azaindoles useful as inhibitors of janus kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130237516-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237516-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-12 | — | — | US | disclosed |
| US-8450489-B2 | Azaindoles useful as inhibitors of janus kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450489-B2 | Azaindoles useful as inhibitors of janus kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120165307-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165307-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| US-8163917-B2 | Azaindoles useful as inhibitors of Janus kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163917-B2 | Azaindoles useful as inhibitors of Janus kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-20100311743-A1 | Azaindoles Useful as Inhibitors of Janus Kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100311743-A1 | Azaindoles Useful as Inhibitors of Janus Kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-09 | — | — | US | disclosed |
| US-7767816-B2 | for treating proliferative disorders, cardiac disorders, neurodegenerative disorders, autoimmune disorders, conditions associated with organ transplantation, inflammatory disorders, and/or immunologically mediated disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-03 | — | — | US | disclosed |
| US-7767816-B2 | for treating proliferative disorders, cardiac disorders, neurodegenerative disorders, autoimmune disorders, conditions associated with organ transplantation, inflammatory disorders, and/or immunologically mediated disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-03 | — | — | US | disclosed |
| US-20070203142-A1 | for treating proliferative disorders, cardiac disorders, neurodegenerative disorders, autoimmune disorders, conditions associated with organ transplantation, inflammatory disorders, and/or immunologically mediated disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-30 | — | — | US | disclosed |
| US-20070203142-A1 | for treating proliferative disorders, cardiac disorders, neurodegenerative disorders, autoimmune disorders, conditions associated with organ transplantation, inflammatory disorders, and/or immunologically mediated disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203142-A1 | for treating proliferative disorders, cardiac disorders, neurodegenerative disorders, autoimmune disorders, conditions associated with organ transplantation, inflammatory disorders, and/or immunologically mediated disorders | JAK1, JAK3, MYLK2 | JAK3 2/4885ROCK2 328/4885CDK9 140/4885 |
| US-20120165307-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JANUS KINASES | JAK3, JAK1, JAK2 | JAK3 1/4885ROCK2 243/4885CDK9 72/4885 |
| US-20130237516-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JANUS KINASES | JAK3, JAK1, JAK2 | JAK3 1/4885ROCK2 243/4885CDK9 72/4885 |
| US-20100311743-A1 | Azaindoles Useful as Inhibitors of Janus Kinases | JAK3, JAK1, JAK2 | JAK3 1/4885ROCK2 243/4885CDK9 72/4885 |
| US-20140357557-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | JAK2, JAK3, JAK1 | JAK3 2/4885ROCK2 1426/4885CDK9 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.